Abstract

AbstractThis chapter is not intended to give an expansive and detailed review of all ofthe methods and assays used for drug‐drug interaction (DDI) assessment during small molecule drug (SMD) development because this has already been accomplished by others in the field. Rather, general concepts and methods will be discussed for some of the typical assays undertaken in SMD development, including whether these methods can be, should be, or already have been applied in the context of therapeutic protein (TP)‐DI assessments. This chapter serves as a starting point for understanding the complexity and difficulties in assessing TP‐DIs.

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call

Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.